MELVILLE, N.Y., Nov. 19, 2015 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCQB:BRTX), a life sciences company focused on stem cell-based therapies, today announced the United States Patent and Trademark Office has issued a US patent covering methods related to BRT's metabolic program (ThermoStem® Program).
The patent allows for the protection of methods of production of generating stem cells and stem cell lines from brown adipose tissue (brown fat) under xeno-free (animal-free) conditions utilizing a proprietary differentiating medium. The technology is applicable for potential therapeutic uses for treating a wide range of degenerative and metabolic disorders, including but not limited to diabetes, hypertension, cardiac deficiency and obesity. In addition, this patent allows for the development of novel human brown adipose cell lines that may be used for high-throughput small molecule screens in drug development and other compounds that play a role in regulating a variety of processes.
Brown adipose tissue is a specialized adipose tissue found in the human body that plays a key role in the evolutionarily conserved mechanisms underlying thermogenesis (generation of non-shivering body heat) and energy homeostasis in mammals - long known to be present at high levels in hibernating mammals and human newborns. This metabolic activity of brown adipose tissue is of great interest as a potential target to treat metabolic disorders and obesity using cell or pharmaceutical intervention.
This is the second patent issued within two months, as the Company earlier announced a patent for its curved needle device.
"The issuance of this first metabolic patent is a significant accomplishment for the Company as we look to build a portfolio of intellectual property around our brown fat program," said Mark Weinreb, President and CEO. "We are excited about the potential of our proprietary stem cell technology in the treatment of metabolic disorders such as diabetes and hypertension, and are committed to protecting it through further patent applications as we seek to advance the program toward clinical trials."
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:
- Disc/Spine Program: Our lead cell therapy candidate, brtxDISC™ (Disc Implanted Stem Cells), is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. We intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The treatment involves collecting a patient's own stem cells, culturing and cryopreserving the cells, and then having a physician inject brtxDISC™ into the patient's damaged disc in an outpatient procedure. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery.
- Metabolic Program (ThermoStem®): We are developing an allogeneic cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue ("BAT"). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. The Company is a party to a research agreement with Pfizer with regard to the study of brown fat.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.